



INDEPENDENT AUDITOR'S REPORT

To the Members of Betabio Pharm Private Limited

Report on the Audit of the Financial Statements


Auditor's Opinion

We have audited the accompanying financial statements of **Betabio Pharm Private Limited** ("the Company"), which comprise the balance sheet as at March 31, 2023, and the statement of Profit and Loss and notes to the financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2023, and its loss for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the



Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards



specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken based on these financial statements.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our



auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the order") issued by the Central Government in terms of Section 143(11) of the Act, we report that the said order does not apply to the Company.
2. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.



- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- (c) The Balance Sheet and the Statement of Profit and Loss dealt with by this Report agree with the books of account.
- (d) In our opinion, the aforesaid financial statements comply with the Indian Accounting Standards prescribed under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- (e) On the basis of the written representations received from the directors as on 31st March 2023 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March 2023 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) With respect to adequacy of the internal financial control over financial reporting of the company and operating effectiveness of such controls is not applicable as the company falls under the exception stated in section 143(3)(i) of the Companies Act, 2013.
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended.
- In our opinion and to the best of our information and according to the explanations given to us, the company is not a Public Company, hence the provisions of section 197 of the Act is not applicable to the company.
- (h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules,



2014, as amended, in our opinion and to the best of our information and according to the explanations given to us:

- I. The Company does not have any pending litigations which would impact on its financial position.
- II. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- III. There were no amounts which were required to be transferred to the investor's education and protection fund by the company.
- IV. (i) The Management has represented that, to the best of their knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(ii) the management has represented, that, to the best of their knowledge and belief, no funds have been received by the company from any person(s) or entity (ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner



whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

(iii) Based on such audit procedures, nothing has come to our notice that has caused them to believe that the representations under sub-clause (i) and (ii) contain any material misstatement.

V. The company has not declared or paid any dividend during the year.

NHPC & Co.

Chartered Accountants

Firm's Reg. No-: 157870W

Haresh

Haresh Amarnani

Partner

Membership No- 187196

UDIN: 23187196BHAJBP1237



Place : Vadodara

Date : 22/09/2023

Betabiopharm Private Limited
US1909GJ2022PTC135997
Balance sheet as at March 31 2023

			(₹ in Lakhs)
Sr. No.	Particulars	Note No.	As at March 31 2023
I	EQUITY AND LIABILITIES		
1	SHAREHOLDERS' FUNDS		
	(a) Share Capital	3	11.00
	(b) Reserves and Surplus	4	(1.12)
	(c) Money received against share warrants		-
			9.88
2	SHARE APPLICATION MONEY PENDING ALLOTMENT		-
3	NON CURRENT LIABILITIES		
	(a) Long Term Borrowings		-
	(b) Deferred tax liabilities (Net)		-
	(b) Other Long term Liabilities		-
	(d) Long Term Provisions		-
4	CURRENT LIABILITIES		
	(a) Short Term Borrowings		-
	(b) Trade Payables		-
	Total outstanding dues of micro enterprises and small enterprises	5	64.85
	Total outstanding dues of creditors other than micro enterprises and small enterprises		-
	(c) Other Current Liabilities		-
	(d) Short-Term Provisions		-
			64.85
	Total		74.73
II	ASSETS		
1.	NON CURRENT ASSETS		
	(a) Property, Plant & Equipment & Intangible Assets		
	(i) Property, Plant & Equipment		-
	(ii) Intangible Assets		-
	(iii) Capital Work-in-Progress		-
	(iv) Intangible Assets under Development		-
	(b) Non Current Investments	6	0.33
	(c) Deferred Tax Asset (Net)		-
	(d) Long Term Loans and Advances	7	0.15
	(e) Other Non Current Assets		-
			0.48
2.	CURRENT ASSETS		
	(a) Current Investments	8	26.38
	(b) Inventories	9	32.30
	(c) Trade Receivables	10	0.98
	(d) Cash and Cash Equivalents	11	14.59
	(e) Short Term Loans and Advances		-
	(f) Other Current Assets		-
			74.25
	Total		74.73


Significant Accounting Policies &

Notes forming part of the financial statements

The Notes referred to above form an Integral part of this statement

As per our attached report of even date

For NHPC & Co.
Chartered Accountants
Firm Registration No. 157870W


Haresh Amarnani
Partner
Membership No: 187196
UDIN : 23187196BHAJBP1237

Place : Vadodara
Date : 22nd September 2023



For and on behalf of the Board of Directors of,
Betabiopharm Private Limited

 
Jasmina Alidassani Sonu Meena
Director Director
DIN: 00584951 09758971

Place : Vadodara
Date : 22nd September 2023


BetabioPharm Private Limited
US1909GJ2023PTC135997
Statement of Profit and Loss for the year ended March 31 2023

(₹ in Lakhs)

Sr. No.	Particulars	Note	2022-23
1	INCOME		
	Revenue from operations	12	36.97
	Other Income		-
	Total Income		36.97
2	EXPENSES		
	Cost of Raw Materials Consumed		-
	Purchases of Stock-in-Trade	13	62.42
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	14	(26.38)
	Employee Benefits Expense	15	0.13
	Finance costs		-
	Depreciation & Amortization		-
	Other expenses	16	2.25
	Total expenses		38.42
3	Profit before exceptional and extraordinary items and tax		(1.46)
	Exceptional items		-
4	Profit before extraordinary items and tax		(1.46)
	Extraordinary items		-
5	Profit before tax		(1.46)
6	Tax expenses		
	Current tax		-
	MAT Credit Entitlement		-
	Deferred Tax Income		(0.33)
	Adjustment for Earlier Year		-
	Total Tax Expenses		(0.33)
7	Profit (Loss) for the period from continuing operations		(1.12)
8	Profit/(loss) from discontinuing operations		-
	Tax expense of discontinuing operations		-
	Profit/(loss) from discontinuing operations (after tax)		-
9	Profit (Loss) for the period		(1.12)
	Earnings Per Equity Share		
	Basic & Diluted Earnings Per Share		(1.02)
	Face Value per Share (in ₹)		10.00
Significant Accounting Policies & Notes forming part of the financial statements:		1-21	

The Notes referred to above form an integral part of this statement
As per our attached report of even date

For NHPC & Co.
Chartered Accountants
Firm Registration No. 157870W


Haresh Amarnani
Partner
Membership No: 187196
UDIN : 23187196BHBJBP1237



Place : Vadodara
Date : 22nd September 2023

For and on behalf of the Board of Directors of,
BetabioPharm Private Limited


Jasmina Alldassani
Director
DIN: 00554951


Sonali Meena
Director
09758971

Place : Vadodara
Date : 22nd September 2023

1 Corporate Information

Betabiopharm Private Limited ("the Company") has been incorporated on 7th October 2022 vide Company Registration No. U51909GJ2022PTC135997 and having its registered office at FF- 127, Winsor Plaza, Nr. Express Hotel, Alkapuri, Vadodara- 39007, Gujarat. The Company is engaged in the business of trading of pharmaceuticals products.

2 SIGNIFICANT ACCOUNTING POLICIES:

(a) Basis of preparation

The financial statements of the Company have been prepared in accordance with the Generally Accepted Accounting Principles in India in accordance with the generally accepted accounting principles, provisions of the Companies Act, 2013 and Accounting Standards (AS) notified u/s 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014. The financial statements have been prepared on accrual basis under the historical cost convention. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year.

(b) Use of estimates

The preparation of financial statements in conformity with Indian GAAP requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

(c) Inventories

Inventories are measured at the lower of cost and net realisable value. The cost of inventories is based on weighted average method, and includes expenditure incurred in acquiring the inventories, and other costs incurred in bringing them to their present location and condition.

(d) Revenue recognition

Revenue from Sale of Products is recognised when the significant risk and rewards of ownership is transferred to the customers.

Sales represents invoiced value of goods supplied net of returns, adjustments towards price variations, discounts etc., but excludes GST.

Interest income is recognized on a time proportion basis taking into account the amount outstanding and the applicable interest rate.

Interest Subsidy & Insurance Claim is recognized and accounted on receipt basis.

Income and expenditure are recognized and accounted for on accrual basis.

(e) Income Taxes

Tax expense comprises of current and deferred tax. Current income tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income-tax Act, 1961 enacted in India. Deferred income taxes reflects the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier years.

Deferred tax is measured based on the tax rates and the tax laws enacted or substantively enacted at the balance sheet date. Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred tax assets and deferred tax liabilities relate to the taxes on income levied by same governing taxation laws. Deferred tax assets are recognised only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised. In situations where the Company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognised only if there is virtual certainty supported by convincing evidence that they can be realised against future taxable profits.

At each reporting date the Company re-assesses unrecognised deferred tax assets. It recognises unrecognised deferred tax assets to the extent that it has become reasonably certain or virtually certain, as the case may be that sufficient future taxable income will be available against which such deferred tax assets can be realised.

MAT credit is recognised as an asset only when and to the extent there is convincing evidence that the company will pay normal income tax during the specified period. In the year in which the Minimum Alternative tax (MAT) credit becomes eligible to be recognized as an asset in accordance with the recommendations contained in Guidance Note issued by the Institute of Chartered Accountants of India, the said asset is created by way of a credit to the statement of profit and loss account and shown as MAT Credit Entitlement. The Company reviews the same at each balance sheet date and writes down the carrying amount of MAT Credit Entitlement to the extent there is no longer convincing evidence to the effect that Company will pay normal Income Tax during the specified period.

(f) Earnings Per Share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting attributable taxes) by the weighted average number of equity shares outstanding during the period.

For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

(g) Cash and Cash Equivalents

Cash and Cash Equivalents for the purposes of cash flow statement comprise cash at bank and in hand and short-term investments with an original maturity of three months or less.

(h) Provisions, Contingent Liabilities and Contingent Assets

A provision is recognized when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made based on technical evaluation and past experience. Provisions are not discounted to its present value and are determined based on management estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current management estimates.

Contingent assets are neither recognized nor disclosed in the financial statements. Contingent liabilities are not recognized but are disclosed by way of notes.



Jasmina

Copy

(₹ in Lakhs)

		As at March 31 2023
3	SHARE CAPITAL	
3.1	Equity share capital	
	Authorised Share Capital : 110000/- equity shares of ₹ 10 each with voting rights	11.00
	Issues, subscribed and fully paid-up share Capital : 110000/- equity shares of ₹ 10 each with voting rights	11.00
	TOTAL	11.00

3.2 The reconciliation of the number of shares outstanding

Particulars	No. of Shares
Equity Shares with voting rights at the beginning of the year	-
Add : Shares issued during the year	1,10,000
Less : Shares bought back during the year	-
Equity Shares with voting rights at the end of the year	1,10,000

3.3 Details of shareholders holding more than 5% shares in the Company

Particulars	As at March 31 2023	
	No of Shares	% held
Jasmina Prem Aildasani	52,250	47.50%
Shivam Malviya	52,250	47.50%

3.4 Details of shares held by Promoters

Particulars	As at March 31 2023	
	No of Shares	% held
Jasmina Prem Aildasani	52,250	47.50%
Shivam Malviya	52,250	47.50%
Chiragkumar Bipinbhai Shah	3,300	3.00%
Sonu Meena	2,200	2.00%

3.5 Company has one class of shares i.e. Equity shares having a par value of ₹ 10 per share. Each holder of equity share is entitled to one vote per share. Equity Shareholders are eligible to dividend proposed by the Board of Directors as approved by Shareholders in the ensuing Annual General Meeting. In the event of liquidation of the company, the holders of equity share will be entitled to receive remaining assets of the company in proportion to the equity shares held after distribution of all preferential amount.

3.6 The Company has not reserved any equity shares for issue under options or under any contracts/commitments or under any agreements etc.

3.7 The Company has not allotted any equity shares as fully paid up pursuant to any contracts or as bonus shares nor bought back any equity shares during the period of five years immediately preceding the reporting date.

(₹ in Lakhs)

		As at March 31 2023
4	RESERVES AND SURPLUS	
	(a) Surplus in the statement of profit and loss	
	Balance as at the beginning of the year	(1.12)
	Add: Surplus for the year	(1.12)
	TOTAL	(1.12)



Jasmina
Sony

(₹ in Lakhs)

5 TRADE PAYABLES		As at March 31 2023
(a) Dues to Micro and Small Enterprises		-
(b) Dues to creditors other than Micro and Small Enterprises		64.85
TOTAL		64.85

Outstanding as on 31st March 2023 for following periods from due date of payment

(₹ in Lakhs)

PARTICULARS	Less Than 1 Year	1-2 Year	2-3 Years	More than 3 Years	Total
MSME	-	-	-	-	-
Others	64.85	-	-	-	64.85
Disputed dues - MSME	-	-	-	-	-
Disputed dues - Others	-	-	-	-	-
TOTAL	64.85	-	-	-	64.85

(₹ in Lakhs)

6 Deferred Tax Asset (Net)		As at March 31 2023
(a) Business loss		1.46
Net Deferred Tax Asset on above		0.33
Opening balance of deferred tax		-
Net deferred income/ (expense) for the year		0.33
Net Deferred Tax Assets/ (Liability)	TOTAL	0.33

(₹ in Lakhs)

7 Other Non Current Assets		As at March 31 2023
(a) Security Deposits		0.15
TOTAL		0.15

(₹ in Lakhs)

8 INVENTORIES		As at March 31 2023
(a) Stock in trade		26.38
TOTAL		26.38

(₹ in Lakhs)

9 TRADE RECEIVABLES		As at March 31 2023
(a) Unsecured, considered good		32.30
(b) Considered doubtful		-
Less: Provision for doubtful debts		-
TOTAL		32.30

Outstanding as on 31st March 2023 for following periods from due date of payment

(₹ in Lakhs)

Particulars	Less than 6 months	6 months-1 Years	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed trade receivable-considered good	32.30	-	-	-	-	32.30
Undisputed trade receivable-considered doubtful	-	-	-	-	-	-
Disputed trade receivable-considered good	-	-	-	-	-	-
Disputed trade receivable-considered doubtful	-	-	-	-	-	-
Total	32.30	-	-	-	-	32.30

(₹ in Lakhs)

10 CASH AND BANK BALANCES		As at March 31 2023
Balances with banks: In Current Accounts		0.98
TOTAL		0.98

(₹ in Lakhs)

11 SHORT TERM LOANS AND ADVANCES		As at March 31 2023
Unsecured and considered good		10.00
Other loans and advances		4.59
Balance with government authority		-
TOTAL		14.59



Jasmina *Sany*

BetabioPharm Private Limited
Notes to the Financial Statements for the year ended 31 Mar 2023

		(₹ in Lakhs)
		2022-23
12	REVENUE FROM OPERATIONS	
(a)	Sale of Goods	36.97
TOTAL		36.97

		(₹ in Lakhs)
		2022-23
13	PURCHASES OF STOCK-IN-TRADE	
(a)	Purchases of Stock-In-Trade	62.42
TOTAL		62.42

		(₹ in Lakhs)
		2022-23
14	CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND STOCK-IN-TRADE	
(a)	Opening stock of stock in trade	-
(b)	Less: Closing Stock of stock in trade	26.38
TOTAL		(26.38)

		(₹ in Lakhs)
		2022-23
15	EMPLOYEE BENEFITS EXPENSE	
(a)	Salaries, Wages, Bonus and Other Benefits	0.13
TOTAL		0.13

		(₹ in Lakhs)
		2022-23
16	OTHER EXPENSES	
(a)	Power and fuel	0.05
(b)	Legal and professional fees	0.61
(c)	Rent expense	0.90
(d)	Repairs to building	0.11
(e)	Telephone and internet expense	0.05
(f)	Audit fees	0.25
(g)	Office expense	0.08
(h)	Miscellaneous expenses	0.20
TOTAL		2.25

16.1	Payments to auditor include auditors' remuneration in respect of:	
(a)	Statutory Audit	0.25
TOTAL		0.25

		2022-23
17	EARNINGS PER SHARE	
Profit Available to Equity shareholders		
	Profit After Tax (A)	(1.12)
	Number of Equity Shares	1,10,000.00
	Weighted Average number of Equity Shares Outstanding (B)	1,10,000.00
Basic & Diluted Earnings per Share (A/B) (In ₹)		(1.02)
Face Value Per Equity Shares (In ₹)		10.00



Jasmina Sanyal

18 RELATED PARTY DISCLOSURES

Names of the related parties and related party relationship
Related parties where control exists

Jasmina Prem Aildassani	Director
Shivam Mulviya	Director
Chiragkumar Bipinbhai Shah	Director
Sonu Meena	Director

Enterprises over which key management personnel or their relatives and/or holding company has significant influence.

Balaji Steroids & Hormones Pvt. Ltd.

Particulars	(₹ in Lakhs)
	Enterprise having control over the company As at March 31 2023
Purchase of Materials Balaji Steroids & Hormones Pvt. Ltd.	8.25
Payable as at 31st March Balaji Steroids & Hormones Pvt. Ltd.	64.60

19 CONTINGENT LIABILITY

	As at March 31 2023
(a) Claims against the company not acknowledged as debt	NIL
(b) Guarantees	NIL

20 CAPITAL COMMITMENTS

	As at March 31 2023
(a) Estimated amount of contracts remaining to be executed on capital account and not provided for.	NIL

21 ACCOUNTING RATIOS

Sr. No.	Name of the Ratio	Measurement	Numerator	Denominator	31-03-2023
1	Current Ratio	Times	Current Assets	Current Liabilities	1.14
2	Debt - Equity Ratio	Times	Total Debt (represents lease liabilities)	Shareholder's Equity	NA
3	Debt Service Coverage Ratio	Times	Earnings available for debt service	Debt Service	NA
4	Return on Equity	%	Net Profits after taxes	Average Shareholder's Equity	-11.39%
5	Inventory Turnover Ratio	Times	Revenue	Average Inventory	1.37
6	Trade Receivables Turnover Ratio	Times	Revenue	Average Trade Receivable	1.14
7	Trade Payables Turnover Ratio	Times	Revenue	Average Trade Payables	1.00
8	Net Capital Turnover Ratio	Times	Revenue	Average Working Capital	3.94
9	Net Profit Ratio (in %)	%	Net Profit	Revenue	-3.04%
10	Return on Capital Employed (in %)	%	Earning before interest and taxes	Capital Employed	-13.26%
11	Return on Investment (in %)	%	Income generated from investments	Time weighted average investments	-11.39%

For NHPC & Co.
Chartered Accountants
Firm Registration No. 157870W

Haresh Amarnani

Haresh Amarnani
Partner
Membership No: 187196
UDIN: 23187196RHAJBP1237

Place: Vadodara
Date: 22nd September 2023

For and on behalf of the Board of Directors of,
BetaBiopharm Private Limited

Jasmina Prem Aildassani
Sonu Meena

Jasmina Aildassani Sonu Meena
Director Director
DIN: 00584951 09758971

Place: Vadodara
Date: 22nd September 2023

